Blavatnik Len's Form 4 filing
Day One Biopharmaceuticals, Inc. (DAWN) · filed Jan 20, 2022
- Accession no.
- 0001209191-22-004174
- Filed
- Jan 20, 2022, 6:37 PM ET
- Trade date
- Jan 18-20, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $1.55M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Blavatnik LenCIK 0001326628 | Other: Affiliate of 10% Owner |
| Access Industries Holdings LLCCIK 0001391297 | Other: Affiliate of 10% Owner |
| Access Industries Management, LLCCIK 0001508226 | Other: Affiliate of 10% Owner |
| AI Day1 LLCCIK 0001863302 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 18, 2022 | Common Stock | PPurchaseAcquired | +43,429 | $14.26F1 | +$619,367.03 | 9,421,205 | Direct | |
| Jan 19, 2022 | Common Stock | PPurchaseAcquired | +58,818 | $14.70F3 | +$864,565.78 | 9,480,023 | Direct | |
| Jan 20, 2022 | Common Stock | PPurchaseAcquired | +4,615 | $14.73F4 | +$67,975.72 | 9,484,638 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $14.53, inclusive. The reporting person undertakes to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.16 to $14.75, inclusive. The reporting person undertakes to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.75, inclusive. The reporting person undertakes to provide to Day One Biopharmaceuticals, Inc., any security holder of Day One Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.